A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

July 22, 2009

ARV Therapy of Little Benefit in Preventing Anal Cancer

by Tim Horn

ARV therapy may not afford much protection against anal cancer among HIV-positive people, according to sobering study results reported Wednesday, July 22, at the Fifth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town. In fact, according to the Veterans Administration analysis reported by Nancy Crum-Cianflone, MD, of the Naval Medical Center in San Diego, rates of anal cancer are progressively increasing.

Since potent antiretroviral (ARV) drug combinations began prolonging lives of HIV-positive people in the late 1990s, cancers originally not linked to HIV have become more prevalent in patients otherwise responding well to HIV treatment. Researchers have long suspected that anal cancer appears to occur at higher rates among HIV-infected people. What hasn’t been clear, however, is whether ARV therapy potentially reduces the risk of anal cancer—perhaps by boosting the immune response to better control human papillomavirus infection, a leading cause of anal cancer—or whether ARV therapy has little effect on its incidence.

The study reported by Crum-Cianflone evaluated rates of, and risk factors for, anal cancer—squamous cell carcinomas—using data from a VA cohort study started in 1985. A total of 5,029 HIV-positive individuals were included in the analysis.

According to Crum-Cianflone, anal cancer rates increased fivefold from the early years of the epidemic from 17 per 100,000 patient years (PYs) to 91 per 100,000 PYs with the advent of combination ARV therapy in the late 1990s. Rates of new anal cancer diagnosis in the cohort continued to increase at an astonishing rate, reaching 244 per 100,000 PYs in 2006 to 2008.

Twenty HIV-positive individuals were included in the analysis looking at anal cancer risk factors. The average age at the time of diagnosed was 41. About 95 percent were male; 55 percent were white; 50 percent had a history of hepatitis B infection; 41 percent had a history of gonorrhea; and 10 percent had a history of syphilis.

The average CD4 count at the time of diagnosis was 375 cells. Forty-one percent had viral loads below 400 copies; 40 percent had an earlier AIDS-related complication; and 75 percent were receiving ARV therapy.

After completing the statistical analysis, Crum-Cianflone’s team found those with anal cancer were more likely to have an earlier AIDS-related complication, a lower CD4 count and a history of more sexually transmitted infections.  

ARV therapy, Crum-Cianflone said, was not shown to effectively reduce the risk of anal cancer in this study.

As HIV patients are living longer, Crum-Cianflone warned, it may allow for sufficient time for anal cancer development, hence rates may continue to increase. She stressed the need for preventive strategies, such as more aggressive screening for precancerous lesions and for anal carcinoma among HIV-infected people.

Search: Anal cancer, antiretroviral, ARV, Nancy, Crum-Cianflone


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    adorableone
    New York
    New York


    newlife202
    JOLIET
    Illinois


    pevans
    San Francisco
    California


    robert12
    Queens
    New York
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.